Table 1.

Unanswered questions related to clinical management of AML patients with the combination Ven/HMA.

(1) Who would be given VEN/HMA?

a. Only > 65 years with adverse genetic and molecular findings?

b. All older patients with AML?

c. Transplant-eligible?

d. Young/adults within ELN-unfavorable risk group?

(2) How to define unfitness to VEN/HMA?

Are all patients selected for single-agent HMA eligible to Ven/HMA?

(3) How to give VEN/HMA?

a. In-/outpatient?

b. Ramp-up dose?

c. Which antifungal prophylaxis should be given?

d. Bone marrow aspirate/biopsy: after cycle 1? Cycle 2?

e. How many courses for definition of refractory ailments?

f. How to select between AZA and DEC?